Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...

ViiV Healthcare, the specialist HIV company majority owned by GSK (LSE: GSK), today announced the presentation of new ...

ViiV Healthcare sponsored events to address the climbing rates of HIV infections on HBCU campuses and the surrounding Black ...

ViiV Healthcare has announced plans to triple its annual supply of long-acting cabotegravir for HIV pre-exposure prophylaxis ...

ViiV’s strategy for CAB LA for PrEP in L&MICs is to maximise rapid access and uptake for populations with highest unmet needs ...

The Indian Patent Office has rejected Viiv Healthcare's patent application for the HIV drug, dolutegravir, after nearly a ...

New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...

Studies from OPERA and Trio cohorts provide further real-world evidence supporting CAB LA for PrEP’s high effectiveness and adherence in preventing HIV acquisition Patient-reported results for CAB LA ...

Alabama State University partnered with ViiV Healthcare during its 2024 Homecoming to address HIV prevention and awareness.

On the campus of Alabama State University, ViiV Healthcare transformed the annual celebration into a platform for HIV ...

ViiV Healthcare’s latest HIV prevention campaign coincided with one of the biggest weekends of the year at Alabama State University.